---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-151300"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-04-10T23:59:59+00:00"
generated_at: "2026-05-15T06:40:56.062107+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Intellia adopts bylaw amendments adding shareholder cure provision and exclusive federal forum clause

## Summary
- Added provision allowing shareholders to cure facially apparent deficiencies in timely nomination or proposal notices.
- Designated U.S. federal district courts as exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934, unless company consents otherwise.
- Amendments effective April 7, 2026, adopted by Board on recommendation of nominating and corporate governance committee.
- Fourth Amended and Restated Bylaws filed as Exhibit 3.1 to this Form 8-K.

## SEC filing metadata
- accession: 0001193125-26-151300
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-04-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526151300/0001193125-26-151300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526151300/d65395d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-151300
- JSON: https://secwatch.observer/filing/0001193125-26-151300.json
- Plain text: https://secwatch.observer/filing/0001193125-26-151300.txt

## Source-grounded claims
- claim_id: beb105748af4f9824a14c6fb81f4271431adafb2
  claim: Intellia Therapeutics, Inc.: Board adopted Fourth Amended and Restated By-laws adding a cure period for deficiencies in shareholder notices and designating federal district courts as exclusive forum for federal securities law actions (effective 2026-04-07).
  evidence_excerpt: On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board adopted amendments to the Company’s Third Amended and Restated By-laws. Under the Fourth Amended and Restated By-laws, which are effective April 7, 2026 (the “Amended By-laws”), the Company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder’s timely notice of a nomination or proposal, and requiring the Company to notify the shareholder of any facially apparent deficiencies in a timely notice. In addition, the Amended By-laws designate the federal district courts of the United States as the exclusive forum for resolving any complaint that asserts a cause of action arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Com
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526151300/0001193125-26-151300-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.